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Abstract
Frailty, the state of increased vulnerability to physical stressors as a result of progressive and sustained degeneration in
multiple physiological systems, is common in those with chronic kidney disease (CKD). In fact, the prevalence of frailty
in the older adult population is reported to be 11%, whereas the prevalence of frailty has been reported to be greater than
60% in dialysis-dependent CKD patients. Frailty is independently linked with adverse clinical outcomes in all stages of CKD
and has been repeatedly shown to be associated with an increased risk of mortality and hospitalization. In recent years
there have been efforts to create an operationalized definition of frailty to aid its diagnosis and to categorize its severity.
Two principal concepts are described, namely the Fried Phenotype Model of Physical Frailty and the Cumulative Deficit
Model of Frailty. There is no agreement on which frailty assessment approach is superior, therefore, for the time being,
emphasis should be placed on any efforts to identify frailty. Recognizing frailty should prompt a holistic assessment of
the patient to address risk factors that may exacerbate its progression and to ensure that the patient has appropriate
psychological and social support. Adequate nutritional intake is essential and individualized exercise programmes
should be offered. The acknowledgement of frailty should prompt discussions that explore the future care wishes of these
vulnerable patients. With further study, nephrologists may be able to use frailty assessments to inform discussions with
patients about the initiation of renal replacement therapy.
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Introduction
Frailty is a state of increased vulnerability to physical stressors,
such as illness or trauma, with an associated increased risk of
poor clinical outcomes [1]. This occurs as the result of a progres-
sive and sustained degeneration inmultiple physiological systems
and, some would argue, also the result of a decline in psychologi-
cal health and inadequate social support [1–3]. In isolation these
deficits may not be considered severe enough to be classified as a
disease state or to require the individual to need additional care
[2]. It is the accumulation of multiple deficits across various sys-
tems that is thought to be fundamental to the development of
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frailty [2]. In recent years there have been efforts to create an
operationalized definition of frailty to aid in its diagnosis and to
categorize its severity. Two principal concepts are described: the
Fried Phenotype Model of Frailty, which focuses on physical
frailty, and the more holistic Cumulative Deficit Model of Frailty,
also known as the Frailty Index, which takes into account a broad
range of medical and psychological conditions and considers
functional impairments [2, 4–8].
Frailty is common in those with chronic kidney disease
(CKD). The prevalence of frailty in the community-dwelling
older adult population is reported to be 11%, whereas studies
have reported a frailty prevalence of > 60% in dialysis-
dependent CKD patients [9–11]. The Atherosclerosis Risk in
Communities (ARIC) Study demonstrated that frailty is strongly
associated with progressive renal impairment [12].
Furthermore, frailty is independently linked with adverse clini-
cal outcomes in all stages of CKD and has been repeatedly
shown to be associated with an increased risk of mortality and
hospitalization [9, 10, 13–16].
Given the convincing relationship between frailty and
adverse outcomes in those with CKD, nephrologists should be
more aware of the concept of frailty. This is particularly true
during interactions with other health care providers, such as
general practitioners and geriatric medicine physicians, who
will assess frailty in the renal population and use the diagnosis
as part of decision making. The European Renal Best Practice
(ERBP) Working Group recently released a clinical practice
guideline on the management of older patients with CKD Stage
3b or higher [17]. They emphasized the importance of assessing
functional decline in older frail patients with advanced CKD,
although they conceded that there was insufficient evidence to
recommend a specific frailty scoring tool [17]. So where does
this leave the practising nephrologist? How should we screen
for frailty in those with CKD? Are scores and tools better than
clinical acumen, and if so, which should be used? What’s more,
if we identify frailty, what can we do for our patients? Here we
provide a focused review of frailty in the renal population with
an emphasis on learning points for the general nephrologist.
We also provide a brief review of the recent literature and high-
light areas of uncertainty and controversy with a need for fur-
ther research.
Why does physical frailty occur in those with
CKD?
Patients with advanced CKD often have a reduced energy intake
that contributes to sarcopenia and, subsequently, physical
frailty [18, 19]. Studies have shown that there is in fact a pro-
gressive decline in food intake with deteriorating kidney
function [18, 20, 21]. The reduced energy intake is frequently
due to anorexia, which is present in up to one-third of patients
with end-stage renal disease (ESRD) [18, 22]. The loss of appetite
that occurs in CKD is likely multifactorial; potential contributors
include the uraemic milieu, inflammation, superimposed ill-
nesses, medications and coexistent low mood [18, 19]. It has
been postulated that the accumulation of uraemic toxins may
cause defects in the hypothalamic regulation of appetite [18].
Furthermore, cognitive impairment is more common in the
CKD population and may lead to reduced food intake [23].
Another dietary challenge for those with CKD is maintaining
adequate protein and energy intake while restricting dietary
phosphate intake to prevent the development of secondary
hyperparathyroidism and CKD–mineral bone disease [24]. This
is particularly difficult in those that are dialysis-dependent as
there are unavoidable losses of amino acids during the dialysis
procedure [25].
Physical activity tends to decrease with ageing and this
decline is more marked for individuals with CKD [26–29].
Notably, patients with dialysis-dependent CKD who maintain
physical activity have superior gait speed, leg strength and lean
body mass [19, 30, 31]. Furthermore, physical inactivity is asso-
ciated with increased mortality in those with CKD, as in the
general population [29, 32]. Hence physical inactivity may be
partly responsible for the reduced lean body mass and, in turn,
the development of sarcopenia and frailty in patients with CKD.
Studies have demonstrated a correlation between pro-
inflammatory cytokines and white blood cell count with frailty
in older adults [33–36]. There are increased levels of pro-inflam-
matory cytokines in CKD, including IL-6 and tumour necrosis
factor alpha (TNF-a) [18, 37–39]. This is likely secondary to a
combination of impaired clearance of cytokines with progres-
sive renal impairment and exposure to inflammatory stimu-
lants, such as uraemic toxins, dialysis and concomitant
infections [19, 37]. The signalling of the anabolic hormones
insulin and insulin-like growth factor 1 (IGF)-1 is impaired by
these pro-inflammatory cytokines by increasing the activity of
glucocorticoids and by directly causing skeletal muscle resist-
ance to insulin and IGF-1 [18, 19, 37, 38, 40]. This incites muscle
protein breakdown via the caspase-3 and ubiquitin proteasome
system [38]. The inflammatory state is also associated with an
increase in resting energy expenditure that may contribute to
the imbalance of muscle protein homeostasis and, in turn, the
frailty syndrome [18, 19].
Metabolic acidosis develops with progressive renal impair-
ment as the ability of nephrons to excrete the daily acid load is
impaired [41]. Metabolic acidosis activates caspase-3 and the
ubiquitin proteasome system, inhibits intracellular signalling of
insulin and IGF-1 and increases adrenal glucocorticoid
production [18, 19, 38]. All of the above result in a state of pro-
tein catabolism that, if it persists, can lead to sarcopenia [41].
Prolactin retention occurs with progressive renal
impairment [18]. This impairs the production of gonadotropic
hormones such as testosterone [18]. Testosterone is an anabolic
hormone that promotes muscle protein synthesis [18].
Testosterone deficiency is frequently present in male individu-
als with ESRD and is independently associated with adverse
outcomes [42]. In earlier stages of CKD, testosterone level was
an independent predictor of muscle mass and strength [43].
Thus low levels of testosterone in men are likely a factor in the
pathophysiology of sarcopenia and, subsequently, frailty.
Low 25-hydroxyvitamin D [25(OH)D] levels are associated
with frailty in the older population [35, 44]. 25(OH)D is hydroxy-
lated to the more active 1,25-dihydroxyvitamin D [1,25(OH)2D]
in the proximal tubule of the kidney [45]. Levels of 1,25(OH)2D
decrease with progressive renal impairment, thus deficiency of
1,25(OH)2D is common in those with CKD [46]. Evidence sug-
gests that vitamin D may act directly on skeletal muscle
through genomic and non-genomic pathways, ultimately
affecting contractile muscle function and muscle metabolism
[45]. Gordon et al. [47] demonstrated that 1,25(OH)2D is a deter-
minant of physical function and muscle size in those with CKD.
It is therefore conceivable that vitamin D deficiency may be a
factor in the development of frailty in CKD, although further
study is needed.
Finally, cellular senescence, loss of telomeric structures,
mitochondrial dysfunction, increased free radical production
and poor DNA repair capability are important in the ageing
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process and in the development of frailty [48]. These processes
occur prematurely in those with CKD and are thought to be the
result of the uraemic milieu [49, 50]. They ultimately lead to sar-
copenia, vascular dysfunction and progressive organ damage
[49, 50]. Although not exhaustive, Figure 1 summarizes funda-
mental mechanisms involved in the pathophysiology of physi-
cal frailty in those with CKD.
Frailty assessment for the nephrologist
In their seminal paper, Fried et al. [4] described the Frailty
Phenotype (FP) as ‘a clinical syndrome involving at least three of
the following: unintentional weight loss, self-reported exhaus-
tion, weakness, slow walking speed and low physical activity’
(Table 1). They demonstrated that their definition of physical
frailty, although having some overlap with disability and
comorbidity, was a distinct syndrome and independently
predictive of adverse outcomes, including falls, hospitalization
and death [4]. Furthermore, the presence of one or two of their
frailty criterion, termed intermediate frailty (or pre-frailty), was
predictive of becoming frail over the subsequent 3–4 years [4].
The FP has been used in several studies involving patients
with CKD. Roshanravan et al. [51] reviewed the outcomes for
those categorized as frail by the FP in patients with CKD Stages
1–4. They established that the FP is associated with a 2.5-fold
[95% confidence interval (CI) 1.4–4.4] increased risk of death or
requiring dialysis in those with CKD [51]. Bao et al. [9] evaluated
the outcomes of those diagnosed as frail at dialysis initiation.
They demonstrated that frailty at dialysis initiation was associ-
ated with an increased risk of mortality [hazard ratio [HR] 1.57
(95% CI 1.25–1.97)] [9]. They also determined that frailty at dialy-
sis initiation was an independent risk factor for first
hospitalization [HR 1.26 (95% CI 1.09–1.45)] [9]. McAdams-
DeMarco et al. [13] assessed the association between frailty and
Fig. 1. Putative mechanisms involved in the pathophysiology of physical frailty in CKD.
Table 1. Operationalized definitions of frailty [2, 4–8]
Phenotype model of physical frailty Cumulative Deficit Model of Frailty
Clinical syndrome involving at least three of the following:
1. Unintentional weight loss
2. Self-reported exhaustion
3. Weakness
4. Slow walking speed
5. Low physical activity
A Frailty Index score is calculated by totaling the number of deficits
from a predetermined list of 30 clinical variables including a broad
range of medical and psychological conditions and functional
impairments.
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mortality and hospitalization risk in those established on dialy-
sis. The authors categorized participants as either non-frail,
intermediately frail or frail [13]. They found that the proportion
of participants admitted to hospital on two or more occasions
over the subsequent year after enrolment was 43% for frail
dialysis-dependent CKD patients compared with 28% for non-
frail dialysis-dependent CKD patients [13]. They also showed
that the 3-year mortality was 40% for frail dialysis-dependent
CKD patients [13]. Notably, 34% of those categorized as inter-
mediately frail died within the 3-year follow-up period, com-
pared with only 16% of those that were categorized as non-frail
[13]. This study thus suggests that differentiating degrees of
frailty may offer even greater clinical utility. In an additional
study, McAdams-DeMarco et al. [52] reviewed the number of
falls occurring over a 6.7-month follow-up period of 95 dialysis-
dependent CKD patients. They used the phenotype definition of
frailty and demonstrated that frailty predicted a 3.09-fold (95%
CI 1.38–6.90) greater number of falls in a dialysis-dependent
CKD population [52]. There was no difference in the association
between frailty and falls for younger and older participants [52].
Notwithstanding the value of the FP, themeasures of weakness
and walking speed present practical issues, specifically the time
and equipment needed to complete the assessments. Therefore,
several studies of CKD populations have used modified versions of
the FP, often substituting questionnaire-based assessments for the
objective measures of weakness and slowness [9, 10, 53–55]. It has
been suggested that questionnaire-based methods of assessing
frailty are more likely to overestimate the prevalence of frailty,
although they still appear to be predictive of outcomes [56–58].
Johansen et al. [10] reviewed the outcomes of those fulfilling the
criteria of a modified version of the FP with dialysis-dependent
CKD. They demonstrated that a modified FP was independently
associated with an increased mortality risk in dialysis-dependent
CKD [HR 2.24 (95% CI 1.60–3.15)] [10]. They also demonstrated that
frailty was associated with an increased risk of the combined
endpoint of hospitalization or death [HR 1.56 (95% CI 1.36–1.79)]
[10]. Interestingly, these outcomes were unrelated to participant
age [10]. Mansur et al. [53] reviewed the association of frailty with
quality of life in CKD patients. They used a modified version of the
phenotype definition of frailty that relied on self-reporting of all
domains. They demonstrated that frailty correlated with poorer
health-related quality of life as measured by the 36-item Short
Form Health Survey (SF-36) [53]. Lee et al. [59] performed a similar
cross-sectional study in 2015. They also demonstrated that amodi-
fied version of the FP was associated with lower health-related
quality of life scores as assessed using the SF-36 [59].
Mitnitski et al. [7] described a contrasting and more holistic
approach to assessing frailty in the general older patient,
namely the Cumulative Deficit Model of Frailty. Rockwood et al.
[5] further developed this model, including a total of 70 variables
consisting of a variety of medical and psychological conditions
and functional impairments. The total number of deficits for an
individual patient was divided by all the predetermined clinical
variables to calculate a Frailty Index (FI) score [5]. Rockwood et
al. [6] subsequently compared the FI with the FP. They per-
formed both measures on 2305 individuals  70 years of age
from the Canadian Study of Health and Aging [6]. They demon-
strated that these operational definitions of frailty correlated
moderately well with each other [6]. They categorized partici-
pants as robust, pre-frail (intermediate frailty) and frail as per
the FP [6]. They demonstrated that increasing FI scores corre-
lated with worse outcomes, specifically with respect to survival
and institutionalization [6]. The FI accurately predicted out-
comes within categories of the FP, suggesting that the FI may be
a more precise measure [6]. Hubbard et al. [60] demonstrated that
frailty can be measured in CKD using an FI. Within their study
there was agreement between an FI and a modified version of
the FP [60]. The FI is challenging to implement into routine clini-
cal care, as at least 30 variables are required to calculate the score
[61–64]. However, with the advent of electronic patient records it
may be possible to overcome this challenge. Clegg et al. [65]
demonstrated that data from primary health care electronic
records can be used to create a FI that is predictive of mortality,
hospitalization and nursing home admission.
Clinicians’ perception of frailty does not correlate well with
measured frailty, therefore there definitely is merit in formally
assessing frailty [66]. Unfortunately, it has not been agreed what
precise operational definition of frailty should be adopted. There
is certainly overlap between both these concepts of frailty.
However, in the general older population and in the CKD popula-
tion, the prevalence of frailty differs depending on the approach
employed [11, 67]. A study performed by Drost et al. [68] effec-
tively demonstrated the inconsistencies in frailty identification
when using different operational definitions of frailty. Their
study population included 95 patients that were either dialysis-
dependent or who had advanced CKD not yet necessitating dialy-
sis [68]. They demonstrated a frailty prevalence of 37% when
using the FI and 27% when using the FP criteria, perhaps because
the FI is a more holistic approach to the concept of frailty [68].
There have been more CKD studies to date that assess frailty
using the FP rather than the Cumulative Deficit Model of Frailty
[67]. There is some progress towards a consensus in gerontology,
namely that it is useful to identify physical frailty for which a tar-
geted management plan can be developed [69, 70]. Given that
currently there is no overall agreement as to which concept of
frailty is superior and as both approaches are associated with
clinical outcomes, arguably it is more important that efforts are
made to identify frailty, regardless of the adopted methodology.
Several frailty screening tools have been developed, although
not all have been used in CKD cohorts [61, 71–77]. Following on
from their work with the FI, Rockwood et al. [5] developed the
Clinical Frailty Scale (CFS), which is a frailty screening tool that
relies on clinical judgement alone. In its original form, the CFS
was a 7-point scale with descriptors for levels of frailty [5]. It has
since been updated to include nine descriptors (Figure 2) [61]. In
their 2005 study, Rockwood et al. [5] demonstrated that the CFS
correlated well with the FI in the general population. Higher
scores on the CFS were also associated with an increased risk of
death [HR 1.30 (95% CI 1.27–1.33)] and institutionalization [HR 1.46
(95% CI 1.39–1.53)] [5]. Alfaadhel et al. [76] demonstrated that CFS
scores at dialysis initiation are associated withmortality. A subse-
quent study showed that the CFS performed in patients pre-
dialysis is an independent predictor of mortality [78]. Iyasere et al.
[75] performed the CFS within their study that compared the
quality of life and physical function in older patients on assisted
peritoneal dialysis and haemodialysis. The authors demonstrated
that higher CFS scores are associated with worse health-related
quality of life scores [75]. We believe that the CFS is a promising
frailty screening tool that could be incorporated into routine clini-
cal nephrology care. Further research is required to establish the
construct validity and interrater reliability of the CFS within CKD
populations given the inherent subjective nature of the tool.
How should we care for the frail patient with
CKD?
The management of frailty is multifaceted and multidisciplinary
given that frailty is the result of multiple deficits. A cornerstone
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of the management of frailty is a holistic medical review. Within
gerontology, the Comprehensive Geriatric Assessment (CGA) is
advocated [1, 79–82]. The CGA is a multidisciplinary, systematic
approach to identify the medical, psychosocial and functional
needs of older adults [79–81]. This allows the formulation of a tar-
geted management plan that should address current medical
conditions and include a medication review, fall prevention
measures and anticipatory care planning (Table 2) [79–83]. The
use of the CGA in the management of older adults has been asso-
ciated with improved outcomes, both in terms of physical func-
tion and survival [79–81]. Recent studies have demonstrated that
it is feasible to use a CGAwithin nephrology care, although further
research is required to assess outcomes [84, 85]. We encourage
nephrology services to consider the development of management
pathways with local gerontology departments so that patients
identified as frail receive specialist geriatric assessment.
Undernutrition is a key contributor to the development of
sarcopenia and frailty in those with CKD [18, 19, 70]. First and
foremost, it is important to address possible causes for reduced
appetite, including medications, uraemia, metabolic acidosis,
intercurrent illness and comorbid conditions such as depression
[24]. Nutritional supplementation may enhance protein anabo-
lism in the general older patient [86, 87]. A Cochrane review
illustrated that calorie supplementation in older adults does
lead to a modest but consistent gain in weight [88]. Cheu et al.
[89] demonstrated that oral nutritional supplementation is
associated with positive outcomes, specifically, fewer hospital
admissions, in those with ESRD and hypoalbuminaemia,
although they did not show any significant effect on survival.
The risks of undernutrition and protein-energy wasting may
outweigh the benefits of strict phosphate control in the frail
CKD cohort, therefore dietary phosphate restriction should be
individualized to allow adequate nutritional intake [17, 90–93].
In fact, recent guidelines state that ‘preserving nutritional sta-
tus should prevail over any other dietary restriction’ [17]. There
is a need for further research that investigates the benefits of
phosphate and potassium restriction compared with dietary
advice more focused at maintaining adequate nutrition.
Fig. 2. The 9-point Clinical Frailty Scale was adapted from the 7-point scale used in the Canadian Study of Health and Aging [5] and has been reprinted with permission
of Geriatric Medicine Research, Dalhousie University, Halifax, Nova Scotia, Canada.
Table 2. Approach to the management of frail patients with CKD
Practice points
1. Holistic assessment and targeted management strategy,
including:
• Treatment of symptomatic medical conditions
• Medication review
• Falls prevention measures
• Anticipatory care planning
2. Nutrition
• Consider causes of reduced appetite
• Dietetic assessment and dietary advice focused on maintain-
ing nutritional status
3. Timely care of complications of CKD
• Metabolic acidosis
• Fluid overload
• Uraemia
4. Individualized exercise training programme
5. Shared decision with the patient regarding the appropriateness of
renal replacement therapy
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Intradialytic parenteral nutrition has been used in dialysis-
dependent CKD, although the evidence to date is limited [19, 24,
94, 95]. It may improve nutritional status, but it has yet to be
shown to have any beneficial effects on survival [19, 24, 94, 95].
Good and timely care of the complications of CKD is essen-
tial to limit the propagation of protein-energy wasting, sarcope-
nia and frailty [19]. As mentioned earlier, metabolic acidosis
develops as renal function declines and is thought to contribute
to the development of sarcopenia [41]. Oral sodium bicarbonate
treatment in those with mild acidosis is associated with an
improvement in nutritional parameters and in muscle strength
[96, 97]. Most guidelines currently recommend administering
oral sodium bicarbonate when the serum bicarbonate concen-
tration falls below 22mmol/L, though the target serum bicar-
bonate level is not well-defined [41, 98]. It is also important to
avoid periods of significant fluid overload that can stimulate
the inflammatory cascade and subsequent protein catabolism
[24]. This requires judicious fluid management that may include
fluid restriction, diuretic therapy and renal replacement therapy
[24]. Lastly, uraemia leads to protein catabolism and subsequent
sarcopenia, therefore the timing of dialysis is likely important—
this is discussed in more detail below [18, 19].
Exercise has well-established, multifaceted benefits for
patients with all stages of CKD, including improvements in
muscle strength, cardiovascular function, physical function and
health-related quality of life [99–101]. Aerobic, resistance and
combined exercise programmes have been investigated and all
have demonstrated benefits for those with CKD [102–112].
Several studies have examined the effects of intradialytic exer-
cise programmes [104, 106, 108, 109, 112]. For example,
Konstantinidou et al. [104] examined the effect of different pro-
grammes and concluded that exercising during non-dialysis
days was most effective, but exercising during dialysis was both
effective and preferable. So it seems that regardless of the form
or mode of exercise, exercise is beneficial for those with CKD.
Exercise training is also associated with improved functional per-
formance in frail older adults [113–117]. Although studies to date
have not directly targeted frailty status as a primary outcome in
frail adults with CKD, it is conceivable that exercise may improve
physical frailty in this patient group, provided there is appropri-
ate consideration of the individual patient’s medical condition
and functional needs. Further work is required to explore the fea-
sibility of a targeted exercise program for frail patients with CKD.
There are potential pharmacological options for frailty under
investigation in those with CKD, although further evidence is
required before they can be recommended in routine clinical
practice [109, 118–123]. Vitamin D replacement is currently rec-
ommended for those that are frail and vitamin D deficient,
although a randomized controlled trial has not yet been per-
formed [70, 123]. The evidence so far has demonstrated that
vitamin D supplementation for those with native vitamin D
deficiency is associated with improved outcomes in the elderly,
including a reduced risk of falls and risk of hip fractures,
improved muscle strength and balance and reduced mortality
[70, 124–128]. Vitamin D supplementation in a CKD cohort was
also linked with an improvement in physical performance [129].
Finally, how does dialysis affect the trajectory of frailty and
should this influence the timing of dialysis or indeed the deci-
sion to commence dialysis at all? Kurella Tamura et al. [130]
assessed the functional status of elderly nursing home resi-
dents before and after commencing dialysis. They demon-
strated that dialysis was associated with a sustained decline in
functional ability rather than an improvement that would
be expected if uraemia alone was thought to be the cause of
their poor performance status [130]. van Loon et al. [131]
also demonstrated that physical performance declines while on
haemodialysis, especially for older patients. These reports
appear at odds with a study by John et al. [132] that demon-
strated that muscle loss is more pronounced pre-dialysis and
that this actually may be ameliorated once dialysis has been
established. One of the main difficulties in establishing how
dialysis affects the trajectory of frailty is that few studies to date
have measured frailty directly and over a sustained period
before and after dialysis initiation. A recent study by Johansen
et al. [133] directly assessed frailty, although participants were
already established on dialysis at the time of assessment. They
demonstrated that there is variability in frailty scores over time,
with a roughly equal difference in those whose frailty scores
improved and those that worsened [133]. It thus remains
unclear precisely how dialysis affects the trajectory of frailty in
patients with advanced CKD. Moreover, in the absence of
randomized controlled trials, it is unclear if dialysis, regardless
of the modality, offers a significant survival benefit over conser-
vative management for frail older patients with advanced CKD
[17, 134, 135]. We recommend that future studies involving
patients with advanced CKD assess the FP so that more direct
comparisons and more definite conclusions can be made. For
the time being, the decision to commence renal replacement
therapy should be made in collaboration with the individual
patient, outlining the perceived risks and benefits within the
context of the limited evidence currently available. If a patient
opts for renal replacement therapy, with the lack of a clear con-
sensus, the choice of modality should be governed by patient
preference and individual circumstances. We believe that the
acknowledgement of frailty in these discussions provides a
meaningful opportunity to discern future care wishes of these
vulnerable patients.
Conclusion
Frailty is not just a problem faced by geriatricians. Frail patients
with CKD are more likely to require hospitalization and more
likely to die than their non-frail counterparts. Therefore, neph-
rologists should actively attempt to identify these vulnerable
patients. With no agreement on which frailty assessment
approach is superior, for the time being emphasis should be
placed on any efforts to identify frailty. Recognizing frailty should
prompt a holistic assessment of the patient to address risk fac-
tors that may exacerbate its progression and to ensure they have
appropriate psychological and social support. Adequate nutri-
tional intake is essential and individualized exercise pro-
grammes should be offered. In the same way that the
assessment of frailty may be used to guide chemotherapy deci-
sions, with further study nephrologists may be able to use frailty
assessments to inform discussions with patients about dialysis
initiation [136, 137]. Finally, acknowledging frailty should prompt
discussions with patients that establish future care wishes.
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